Evidence map›Paper›PMID 17661040›Full record

ArticleCancer chemotherapy and pharmacology2008

Dihydrodiol dehydrogenases regulate the generation of reactive oxygen species and the development of cisplatin resistance in human ovarian carcinoma cells.

Jianli Chen, Mahesha Adikari, Rajash Pallai, Hemant K Parekh, Henry Simpkins

Open access · greenAbstract read
In one paragraph

Article in Cancer chemotherapy and pharmacology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
1.0field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 71 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. ROS-modulated therapeutic approaches in cancer treatment.Journal of cancer research and clinical oncology · 2017
    Review
  18. Article
  19. Article
  20. ROS and ROS-Mediated Cellular Signaling.Oxidative medicine and cellular longevity · 2016
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Jianli ChenDepartment of Pathology and Laboratory Medicine, Temple University School of Medicine, Room 206, OMS, 3400 N. Broad Street, Philadelphia, PA 19140, USA.
Mahesha Adikari
Rajash Pallai
Hemant K Parekh
Henry Simpkins
Temple University · US

Funding

Dihydrodiol dehydrogenase mediates cisplatin resistanceR01CA098804 · NCI · TEMPLE UNIV OF THE COMMONWEALTH · PI SIMPKINS, HENRY · 2003 to 2007
$1.1M
NCI NIH HHS CA98804NCI NIH HHS R01 CA098804
6 · The paper itself

Abstract

We have previously demonstrated that overexpression of dihydrodiol dehydrogenase isoform 1 (DDH1) or DDH2 leads to the induction of drug resistance to platinum based drugs in human ovarian, lung, cervical and germ cell tumor cell lines. DDH belongs to a family of aldoketo reductases that are involved in the detoxification of several endogenous and exogenous substrates. DDH1 and DDH2 in particular have been shown to be involved in the detoxification (activation?) of polycyclic aromatic hydrocarbons (PAH). Based on the involvement of DDH in the detoxification of electrophilic PAH intermediates, the effect of DDH on the production of reactive oxygen species (ROS) in a cisplatin-sensitive and -resistant human ovarian carcinoma cell line was investigated in the current study. In addition to the overexpression of DDH1 and DDH2, increased expression of DDH3 was demonstrated in the cisplatin-resistant 2008/C13* cells, compared to the parental 2008 cells. However, as assessed by RT-PCR, neither cell line expressed DDH4. The 2008/C13* cells were eightfold resistant to cisplatin, and transfection experiments utilizing cisplatin-sensitive 2008 cells suggest that this could be mediated by overexpression of either DDH1, DDH2, or DDH3. The 2008/C13* cells had lower basal intracellular ROS level as compared to the 2008 cells and ROS production was decreased in the recombinant 2008 cells with forced, constitutive overexpression of either, DDH1, DDH2, or DDH3. Transfection of siRNA against DDH1 or DDH2 in the cisplatin-resistant 2008/C13* cells not only significantly decreased their cisplatin-resistance index (as assayed by MTT and colony formation assay) but also led to an increase in the basal levels of ROS production (although transfection of siRNA against DDH3 resulted in cell death). The 2008/C13* cells were found to be cross-resistant to the cytotoxic effects of hydrogen peroxide and tert-butyl hydroperoxide and knockdown of either DDH1 or DDH2 expression (using siRNA) resulted in sensitization of the resistant cells to these agents. These results support the conclusion that the increased levels of DDH in the 2008/C13* cells are directly responsible for the reduced production of ROS and that this may play a role in the development of cisplatin resistance.

Indexed as

Alcohol OxidoreductasesAntineoplastic AgentsBlotting, WesternCell Line, TumorCisplatinClone CellsDrug Resistance, NeoplasmEnzyme InductionEsterasesFemaleHeme Oxygenase (Decyclizing)HumansHydrogen PeroxideIsoenzymesOvarian NeoplasmsOxidative StressAlcohol OxidoreductasesAntineoplastic AgentsCisplatindihydrodiol dehydrogenasesEsterasesheme oxygenase-2Heme Oxygenase (Decyclizing)Hydrogen PeroxideIsoenzymesReactive Oxygen SpeciesRNA, Small Interferingtert-Butylhydroperoxide

Identifiers

PMID17661040
PMCPMC2846169
OpenAlexW2022950108

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.